2020
| Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia | 21.12.2020 (Mihaela Sava) Salama C. et al.: Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia The New England Journal of Medicine Published online December 17, 2020 |
| Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase–Producing Organisms? | 14.12.2020 (Andreas Neumayr) Sharara SL et al.: Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase–Producing Organisms? CID 71 e331–7 2020 |
| Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer | 07.12.2020 (Ana Durovic) G. Shah et al.: Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer NEJM DOI: 10.1056/NEJMc2031670 2020 |
| A randomized Trial of convalescent Plasma in Covid-19 severe Pneumonia | 30.11.2020 (Anne-Valérie Burgener) Simonovich V.A. et al.: A randomized Trial of convalescent Plasma in Covid-19 severe Pneumonia NEJM DOI: 10.1056/NEJMoa2031304 November 24, 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial | 23.11.2020 (Silvio Ragozzino) Ramasamy MN, et al.: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Lancet Published online November 19, 2020 |
| A Randomized Trial Comparing Antibiotics with Appendectomy for Appendicitis | 16.11.2020 (Sabine Kuster) CODA Collaborative, Flum DR, Davidson GH, Monsell SE, et al.: A Randomized Trial Comparing Antibiotics with Appendectomy for Appendicitis N Engl J Med 2020 Nov 12;383(20 1907-1919 |
09.11.2020 (Seraina Bally) | |
| 1) Longitudinal oberservation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans 2) SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | 02.11.20 (Ana Durovic) 1) Seow J. et al 2) Chen P et al: 1)Longitudinal oberservation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans 2) SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 1) Nature microbiology 2) NEJM DOI: https://doi.org/10.1038/s41564-020-00813-8 DOI: 10.1056/NEJMoa2029849 2020 |
| Repurposed antiviral drugs for COVID-19 – interim WHO SOLIDARITY trial results | 19.10.2020 (Sandra Zingg) Repurposed antiviral drugs for COVID-19 – interim WHO SOLIDARITY trial results MedRxiv preprint 2020 |
| Self-Collected Anterior Nasal and Saliva 1 Specimens versus Healthcare Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2 | 12.10.2020 (Kai-Manuel Adam) Hanson KE et. al.: Self-Collected Anterior Nasal and Saliva 1 Specimens versus Healthcare Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2 J. Clin. Microbiol. Epub Epub 2020 |
| Individual quarantine versus active monitoring of contact for the mitigation of COVID-19: a modelling study | 14.09.2020 (Matthias von Rotz) Peak CM. et al.: Individual quarantine versus active monitoring of contact for the mitigation of COVID-19: a modelling study Lancet Infect Dis 20: 1025-33 2020 |
| 1. Setting The criteria for SARS-CoV-2 Reinfection – six Possible cases 2. Clinical recurrences of COVID-19 Symptoms after recovery: Viral relapse, reinfection or inflammatory rebound? 3. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing | 07.09.2020 (Kai-Manuel Adam) |
| Prevalence of Infective Endocarditis in Streptococcal Bloodstream Infections Is Dependent on Streptococcal Species | 31.08.2020 (Ana Durovic) Chamat-Hedemand S. et al.: Prevalence of Infective Endocarditis in Streptococcal Bloodstream Infections Is Dependent on Streptococcal Species Circulation Volume 142, Issue 8 720-730 2020 |
| Risk of COVID-19 in health-care workers in Denmark: an observational cohort study | 24.08.2020 (Sandra Zingg) Iversen K. et al.: Risk of COVID-19 in health-care workers in Denmark: an observational cohort study Lancet Infect Dis 2020 S1473-3099(20)30589-2 2020 |
| Molecular epidemiology of resistance to antimalarial drugs in the greater Mekong subregion: an observational study | 17.08.2020 (Mihaela Sava) Imwong M. et al.: Molecular epidemiology of resistance to antimalarial drugs in the greater Mekong subregion: an observational study THE LANCET Infectious Diseases Epub Epub 2020 Juli |
| Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use | 10.08.2020 (Anne-Valérie Burgener) Rhee, Kadri, Dekker et al.: Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use JAMA Infect. Disease, 2020;3(4):e202899 |
| Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts | 03.08.2020 (Silvio Ragozzino) Ikematsu H. et al.: Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts N Eng J Med 383 309-320 2020 |
| Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia. A Randomized Clinical Trial | 27.07.2020 (Matthias von Rotz) von Dach E. et al.: Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia. A Randomized Clinical Trial JAMA 323, Number 21 2160-2169 June 2, 2020 |
| An mRNA Vaccine against SARS-CoV-2 – Preliminary Report | 20.07.2020 (Sabine Kuster) Jackson L.A. et al.: An mRNA Vaccine against SARS-CoV-2 – Preliminary Report NEJM July 14, 2020 DOI:10.1056/NEJMoa2022483 1-12 |
| Effect of Dexamethasone in Hospitalized Patients with OCVID-19 – Preliminary Report | 13.07.2020 (Sandra Zingg) Peter Horby: Effect of Dexamethasone in Hospitalized Patients with OCVID-19 – Preliminary Report medRvix preprint https://doi.org/10.1101/2020.06.22.20137273 2020 |
| Effect of Colchicine vs. Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial | 29.06.2020 (Sabine Kuster) Deftereos S.G. et al: Effect of Colchicine vs. Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial JAMA Online June 2020, Vol 3, No. 6 1 -14 2020 |
| Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial | 22.06.2020 (Mihaela Sava) Zhu FC et al.: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial The Lancet 395 1845-54 2020 Mai |
| 1. Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection 2. Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study 3. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial | 15.06.2020 (Kai-Manuel Adam) Diverse 3 Paper: 1. Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection 2. Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study 3. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial medRxiv preprint Epub Epub 2020 Juni |
| Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis | 08.06.2020 (Matthias von Rotz) Mehra MR. et al.: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis The Lancet Nur online erschienen. 22. Mai 2020 |
| An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study | 25.05.2020 (Aurélien Emmanuel Martinez) Verdoni L. et al.: An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study Lancet Online online 2020 |
| Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure | 18.05.2020 (Ana Durovic) Kucirka L.M. et al.: Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure ACP Journals doi.org/10.7326/M20-1495 2020 |
| Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospektive observational studies | 11.05.2020 (Anne-Valérie Burgener) Williams CM et al.: Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospektive observational studies Lancet Infect Dis. Volume 20 607-617 |
| An analysis of SARS-CoV-2 viral load by patient age | 04.05.2020 (Silvio Ragozzino) Terry CJ. et al: An analysis of SARS-CoV-2 viral load by patient age Preprint – https://virologie-ccm.charite.de/ |
| No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial | 20.04.2020 (Sandra Zingg) Mahévas M. et al: No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial BMJ (medRxiv) 04/2020 |
| Virological assessment of hospitalized patients with COVID-19 | 06.04.2020 (Mihaela Sava) Wölfel R et al.: Virological assessment of hospitalized patients with COVID-19 Nature 2020, published online April 1st , 2020 |
| Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents | 30.03.2020 (Matthias von Rotz) Kampf G. et al.: Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents Journal of Hospital Infection 104 246-251 2020 |
| Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study | 10.02.2020 (Sabine Kuster) Nashan Chen et al.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Lancet Infectious Disease Published Online January 29, 2020 1-7 2020 |
| Fosfomycin for Injection (ZTI-01) Versus PiperacillinPiperacillintazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial | 20.01.2020 (Elisabeth Wehrle) Kaye K.: Fosfomycin for Injection (ZTI-01) Versus PiperacillinPiperacillintazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial CID 69 2045-2056 2019 |
| Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis oft wo randomised controlled trials | 13.01.2020 (Mihaela Sava) Campbell R J. et al.: Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis oft wo randomised controlled trials Lancet Infect Dis 2019 Online First 2019 |
| Β-Lactam pharmacodynamics in Gram-negative bloodstream infections in critically ill | 06.01.2020 (Sandra Zingg) Gloria Wong: Β-Lactam pharmacodynamics in Gram-negative bloodstream infections in critically ill J Antimicrob Chemother 75 429-433 2020 |